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2014, accepted Janhe severe hypercholesterolemia phenotype includes all patients with marked elevation of low-density lipoprotein
cholesterol (LDL-C) levels. The most common cause is autosomal dominant hypercholesterolemia, an inherited disorder
caused by mutations either in LDL receptor, apolipoprotein B (APOB), or proprotein convertase subtilisin kexin type 9
(PCSK9) genes. However, it is now known that many subjects with severe inherited hypercholesterolemia have
no defects in these genes. These cases are caused either by mutations in genes yet to be identiﬁed or are
consequences of polygenic, epigenetic, or acquired defects. Because the clinical consequences of extreme
hypercholesterolemia are the same no matter the cause, the focus should be on the identiﬁcation of subjects with
severe hypercholesterolemia, followed by phenotypic screening of family members. Genetic screening is not
necessary to diagnose or initiate treatment for the severe hypercholesterolemia phenotype. Management of severe
hypercholesterolemia is based on risk factor modiﬁcation and use of multiple lipid-lowering medications.
Lipoprotein apheresis is indicated for coronary artery disease (CAD) patients taking maximally tolerated therapy and
with LDL-C levels >200 mg/dl (>300 mg/dl if without CAD). A microsomal triglyceride transfer protein inhibitor and
an antisense oligonucleotide against APOB have recently been approved for use in subjects with clinically diagnosed
homozygous familial hypercholesterolemia. PCSK9 inhibitors, currently in phase II and III trials, lower LDL-C up to
an additional 70% in the setting of maximally tolerated medical therapy and have the potential to reduce LDL-C
to <70 mg/dl in most patients. Early identiﬁcation of affected individuals and aggressive treatment should
signiﬁcantly reduce the burden of cardiovascular disease in society. (J Am Coll Cardiol 2014;63:1935–47)
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subjects with low-density lipoprotein cholesterol (LDL-C)
levels above 190 mg/dl, regardless of the cause. The term
autosomal dominant hypercholesterolemia (ADH) is
reserved for patients with mutations in genes controlling
LDL levels. Familial hypercholesterolemia (FH) is a com-
mon monogenic disorder caused by abnormalities in the
LDL receptor (LDLR) protein, commonly inherited in a
codominant fashion (1). Patients can be true FH homozy-
gotes (HoFH), with 2 identical mutations; compound
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uary 7, 2014.FH heterozygotes (HeFH), with only one mutated allele.
ADH includes FH and the hypercholesterolemia resulting
from defects in 2 other major genes, APOB and PCSK9,
which inﬂuence plasma LDL clearance by affecting the
efﬁciency of ligand–receptor interaction. The inadequate
LDL clearance manifested in all forms of ADH leads to
marked elevations of plasma LDL-C levels and premature
cardiovascular disease (CVD) (2). In individuals with true
HoFH, the LDLR pathway is nonfunctional or markedly
defective (2% to 30% activity), leading to plasma LDL-C
levels 4 to 8 times above average (>500 mg/dl), whereas
in patients with HeFH, the loss in receptor activity (up to
50%) leads to LDL-C levels 2 to 3 times above average (3).
Many individuals with LDL-C >190 mg/dl do not have
defects in any of the 3 genes. A polygenic origin is likely in
many of these cases (4), and thus, genetic screening stra-
tegies are not easily endorsable as they pose great challenges
to comprehensive, effective, and economical implementa-
tion. Because the risk of vascular disease is determined by
lifelong exposure to hypercholesterolemia, not by the ge-
notype that produces it, we propose that screening should
focus on identifying subjects with the phenotype without
investing resources in the identiﬁcation of the genetic
causes, as also suggested in a recent editorial by Stein and
Raal (5).
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1936This review summarizes the
state-of-the-art in the identiﬁ-
cation of subjects with the severe
hypercholesterolemia phenotype
and ADH, screening of affected
family members, and established
and emerging treatments.Prevalence of Severe
Hypercholesterolemia
Phenotype and Risk of CHD
Approximately 600,000 people
in the United States and bet-
ween 14 and 35 million people
worldwide manifest the severe
hypercholesterolemia phenotype
(2,6). HeFH is estimated to occur
in 1 of every 200 to 500 persons,
with approximately 10 million
affected worldwide, and the fre-
quency may vary among certainpopulations because of gene founder effects. True HoFH
is rare, with a supposed prevalence of approximately 1 per
1,000,000 persons.
The risk of premature coronary heart disease (CHD)
is estimated to be approximately 20-fold higher in untreated
FH patients than in control subjects (Fig. 1) (7). Fatal or
nonfatal coronary events occur in approximately 50% of
males before age 50 and 30% of females before age 60. Inween Age and
Exposure
s estimated for homozygous familial hyper-
us familial hypercholesterolemia (HeFH), and
cholesterol (LDL-C) levels in normal in-
presents a theoretical threshold of the cumu-
velopment of CHD. The height of the red line
itional CHD risk factors. Reprinted withsubjects with HoFH, sudden death, acute myocardial
infarction (MI), or need for revascularization may occur in
patients in the ﬁrst decade of life (8,9). HoFH also
commonly causes aortic stenosis, both valvular and supra-
valvular, due to lipid deposition in the aortic valve leaﬂets
and aortic root (10). The prevalence of HeFH is higher
among patients with MI, from w5% of patients <60 years
of age to almost 20% in patients <45 years of age (11–13).
Additional risk factors such as smoking, hypertension, dia-
betes, male sex, and low HDL-C (14) further amplify CHD
risk by 2- to 3-fold (15). In addition, elevated lipoprotein (a)
(Lp[a]) levels are common in FH patients, and the trait
seems to be a consequence of FH and is not inherited
separately (16,17). Given that the evidence to date does not
suggest that the LDLR is involved in Lp(a) clearance
(18,19) this suggests that overproduction of APOB, known
to occur in FH (20–23), may be partially responsible for the
overproduction of Lp(a) particles.
Genetics
Our physiological understanding of FH is based on the
pioneering work of Brown and Goldstein (1), who estab-
lished a molecular link among defects in the LDLR gene,
loss of function of LDLR, the cell surface protein that
binds and internalizes LDL particles, and the inherited
hypercholesterolemic trait (1). Although classic FH is still
deﬁned as severe hypercholesterolemia caused by a defect
in the LDLR, a functionally similar effect is caused by
mutations in APOB (the ligand for LDLR) or PCSK9
(the terminator of LDLR lifecycle) (Fig. 2, Table 1)
(24,25), all of which signiﬁcantly impair the function of
the LDLR pathway. Mutations in LDLR are responsible
for approximately 85% to 90% of cases of clinical FH, and
>1,600 mutations have been documented to date (26).
Common mutations in the LDLR gene include deletions,
insertions, and missense and nonsense changes affecting
all of the major steps in LDLR trafﬁcking and function
(Fig. 3) (reviewed in Hopkins et al. [2]). A less common
mutation in APOB leading to poor interaction with the
LDLR (27) is responsible for a phenotype indistinguish-
able from classic FH, except for less drastic elevations in
LDL-C. Additionally, ultrarare monogenic defects can cause
severe autosomal recessive hypercholesterolemia, caused by
defects in a liver-speciﬁc LDLR chaperone LDLR adaptor-
related protein 1 (LDLRAP1) (28) and beta-sitosterolemia
due to the abnormal intestinal absorption of plant sterols
(29), both of which are recessively inherited.
PCSK9 is a secreted convertase that binds to the LDLR
and targets it for lysosomal degradation mostly in the he-
patocyte. Gain-of-function mutations in PCSK9 leading to
elevated plasma LDL-C levels are an uncommon cause of
FH (30). Interestingly, subjects with loss-of-function mu-
tations in PCSK9 have reduced plasma levels of LDL-C and
are signiﬁcantly protected from coronary heart disease
(CAD) (31). Indeed, the extent of protection is
Figure 2 Major Molecular Causes of Familial Hypercholesterolemia
The severe hypercholesterolemia phenotype is caused predominantly by defects in the low-density lipoprotein receptor (LDLR) APOB-100 and PCSK9 (when dominantly inherited)
and by defects in the liver-speciﬁc LDLR adaptor-related protein 1 (LDLRAP1), a chaperone for proper positioning of LDLR on the vascular side of the plasma membrane (when
recessively inherited).
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1937disproportionately large relative to the degree of LDL-C
lowering, which suggests that a lifelong low LDL-C is a
powerful determinant of low CVD risk (Fig. 4).
Although our knowledge of the mechanisms and critical
proteins in the LDL cycle seems to be complete, it has been
frequently reported that 30% to 50% of subjects with a
classic phenotypic presentation of FH have no defects in any
of the culprit genes (32). Thus, multiple genotypes may
produce the FH phenotype, and a phenotypic diagnosis of
FH is not equivalent to diagnosing a monogenic error in the
LDLR pathway (Table 1). In particular, the demonstration
that many individuals with apparent FH have a polygenic
origin to their phenotype (4) has transformed our under-
standing of the genetic architecture of this disease. In
polygenic FH, involvement of family members should be
substantially less common than in classic FH, thus reducing
the efﬁcacy and cost effectiveness of family screening stra-
tegies. Therefore, for practical purposes, FH should beTable 1
Genetic Causes of
Familial Hypercholesterolemia Phenotypes
I. Molecular Defects in the Low-Density Lipoprotein Receptor Pathway
 Deletion, missense, nonsense, and insertion mutations in low-density
lipoprotein receptor (LDLR) affecting receptor function (>1,600 mutations
reported to date);
 Mutations in apolipoprotein B (APOB) that affect the ability of the ligand to
recognize LDLR (most commonly a single base change at position 3,500);
 Gain-of-function mutations in PCSK9 causing a reduction in LDLR on the
cell surface;
 Mutations in LDLR accessory protein 1 (LDLRAP1) causing improper placement
of LDLR on the hepatocyte membrane (a rare and recessively inherited form).
II. Polygenic Hypercholesterolemia
III. Other Monogenic, Epigenetic, and Nongenetic Forms (yet to be discovered)diagnosed at the phenotypic level to avoid the indefensible
position that only real monogenic FH warrants aggressive
intervention. In addition, genetic screening has the potential
to identify “causal” mutations in carriers who, for unclear
reasons, have low LDL-C levels and therefore do not qualify
for therapy. In other words, the phenotype is not the
invariable product of the genotype.Pathophysiology
The liver is the ﬁnal destination for most LDL particles,
which are extracted from plasma either by the LDLR or
by nonspeciﬁc pathways (33,34). Uptake by the LDLR is
based on the speciﬁc binding of APOB to the LDLR,
internalization of the receptor–ligand complex, targeting
of the LDL ligand to the lysosome, and recycling of
LDLR to the cell surface. PCSK9 and inducible degrader
of LDL (IDOL), an E3 ubiquitin ligase, modulate LDL
uptake by the LDLR (30,35) but do not affect the
nonspeciﬁc pathways. Even though LDL particles bind
with high afﬁnity to the LDLR, this pathway has a low
absolute transport capacity, and therefore, the nonspeciﬁc
pathways for LDL clearance are always operational, even
for LDL-C levels approximately 30 mg/dl (11,33). These
pathways are not saturable and therefore present no
absolute limit on the number of LDL particles that can be
removed per day (34). Therefore, the higher the plasma
LDL-C level, the greater the relative and absolute pro-
portions of LDL particles that are cleared by the nonspeciﬁc
pathways (36).
In HeFH, transport through the LDL pathway is
reduced by up to 50%, but absolute hepatic LDL particle
Figure 3 Cellular Processes Mediating LDL Uptake and Causing Familial Hypercholesterolemia
Five major classes of LDLR mutations cause familial hypercholesterolemia (or autosomal dominant hypercholesterolemia [ADH]). In ADH-1, the mutations prevent (i) production
of immunologically detectable protein; (ii) ER exit of complete (a) or partial (b) gene-encoded products; (iii) binding of apolipoprotein B-100 (APOB-100) (a) and apoE (b) ligands;
(iv) constitutive endocytosis, including of low-density lipoprotein receptor (LDLR)-APOB-100 (a) and of very-low-density lipoprotein (VLDL)-apoE (b); and (v) release of internalized
LDLR ligand (not shown for clarity). ADH-2 is caused by APOB mutations that block the binding of APOB-100 to the LDLR. ADH-3 is caused by gain-of-function PCSK9 mutations.
Red, loss-of-function mutation; green, gain-of-function mutation. Reprinted with permission from Calandra et al. (25).
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1938uptake is not reduced. On the contrary, total LDL-C
clearance from plasma is doubled in HeFH and is 4 times
normal in oFH (37). To avoid accumulation within theFigure 4 Role of PCSK9 in Risk of CAD
(A) Distribution of plasma low-density lipoprotein cholesterol (LDL-C) levels at baseline am
is compared with the distribution of levels among the 85 black subjects who did have 1 of
had no evidence of coronary heart disease at baseline and in whom coronary heart disea
millimoles per liter, multiply by 0.02586. Reprinted with permission from Cohen et al. (3hepatocyte, this excess cholesterol is exported within the
APOB-containing lipoprotein, transferred to HDL, excreted
in the bile, or transformed into bile acids. Hepatic cholesterolong 3,278 black subjects who did not have a PCSK9142X or PCSK9679X allele (top)
these two alleles (bottom). (B) Percentage of participants from these 2 groups who
se developed during the 15-year follow-up period. To convert values for LDL-C to
1).
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1939homeostasis is, therefore, partly maintained by the APOB
lipoprotein transport system (16), as suggested by the evi-
dence that secretion of APOB lipoproteins is increased in
FH (38–41). Any increase in LDL production will pro-
duce a disproportionate increase in plasma LDL-C because
the additional LDL particles are cleared through inefﬁcient
pathways. Even in subjects with normal LDLR function,
increases in LDL production will raise LDL-C levels above
normal. In fact, increased production, rather than decreased
clearance, may be the most common cause of elevated
LDL-C (42). Reducing secretion of hepatic APOB lipo-
proteins is, therefore, a physiologically appropriate target to
reduce LDL-C in patients with FH.
Clinical Diagnosis
FH is clinically diagnosed by 5 major criteria including
family history of premature CAD, presence of early CAD
in the index case, elevated LDL-C, tendon xanthomas,
and corneal arcus. HeFH can be suspected when LDL-C
is 190 mg/dl in adults and 160 mg/dl in children.
HoFH should be suspected for LDL-C levels >400 mg/dl
(2). Secondary causes of hypercholesterolemia such as hy-
pothyroidism, nephrotic syndrome, and liver disease should
be ruled out. FH is more likely in individuals with a positive
family history of CAD (before age 55 in men, age 65 in
women), when 2 or more ﬁrst-degree relatives have elevated
LDL-C or when pediatric cases are identiﬁed. Xanthomas
in the Achilles and ﬁnger extensor tendons at any age are
found in approximately 30% to 40% of adults with FH.
Corneal arcus in patients younger than 45 is an insensitive
but speciﬁc ﬁnding. Causative mutations affecting LDL-C
levels are diagnostic, even in the absence of other criteria.
Patients with FH commonly have markedly elevated
LDL-C, normal triglyceride levels, and reduced high-
density lipoprotein cholesterol (HDL-C). Low HDL and
loss of HDL function may be contributors to CVD risk in
FH subjects (43). Universal lipid screening is recommended
in all individuals by age 20 and in children as young as 2 in
the presence of family history of premature CVD or severe
hypercholesterolemia (44).
Validated algorithms may also assist in the clinical diag-
nosis of FH, such as those from the Dutch Lipid Clinic
Network (45) and Simon-Broome Registry (46) (Online
Tables 1 and 2). A downloadable application is also avail-
able online (FH diagnosis; KKIT Creations, LLC, Dana
Point, California).
Genetic Screening
Genetic screening for FH is not needed for clinical man-
agement and not generally covered by medical insurance
but is essential to characterize the defect. Identiﬁcation of a
causal mutation may be helpful in improving a patient’s
compliance with medical therapy, although this has not been
proven. Applying the Simon-Broome criteria, the prevalenceof mutation-positive patients is 30% among subjects with
possible FH and 60% to 80% among those with deﬁnite
FH. Because most severe hypercholesterolemic patients fall
in the range of possible FH, this means that most are
mutation-negative and do not display an obvious genetic
reason for their lipid phenotype. Importantly, a negative
genetic test result does not exclude FH, because many of the
clinically deﬁnite FH patients will not be found to have a
mutation despite an exhaustive search using current
methods. The recognition of a polygenic origin for a sub-
stantial portion of the FH phenotype has considerably
complicated the design and application of any genetic
screening strategy (4,5).
Cascade Screening
Cascade screening is the process of systematic family
tracing to identify people carrying a genetic condition and
is infrequently used in clinical practice, although it is
recommended by most guidelines (47). For FH, it is
carried out by screening lipid proﬁles of close relatives of
the index patient and is the most cost-effective method of
ﬁnding new cases of FH. Because LDL-C levels drive
clinical risk, and it is difﬁcult for physicians to remem-
ber diagnostic criteria for an uncommon disease, we sug-
gest that emphasis be placed on severe hypercholesterolemia
and that recognition of a case be sufﬁcient to initiate
family screening for other individuals with elevated levels
of LDL-C.
Aggressive Lipid Lowering and CVD Outcomes
Aggressive lipid lowering in FH patients has been shown
to decrease progression of angiographically determined
CAD (48) and to reduce CVD events (49,50). For
example, Neil et al. (50) prospectively followed 3,382
patients with HeFH between 1980 and 2006, before and
after introduction of statins. CHD mortality was signiﬁ-
cantly lower among statin users, with a 48% reduction
among patients without prior CVD and a 25% reduction
in those with established disease. Similar ﬁndings were
reported (51) from a large cohort from the Netherlands
(Fig. 5). Raal et al. (49) retrospectively studied 149 pa-
tients with HoFH from 2 specialized lipid clinics in
South Africa before and after lipid-lowering therapy. A
signiﬁcant reduction in major adverse cardiovascular
events was noted with a hazard ratio for beneﬁt from
lipid-lowering therapy of 0.49 (p < 0.0001) (Fig. 6),
following an absolute reduction in LDL-C from 15.9 
3.9 nmol (614.8  150.8 mg/dl) to 11.7  3.4 nmol/l
(452.4  131.5 mg/dl) (26.4%). Although no ran-
domized clinical trials of statin efﬁcacy have been done in
HeFH, the 4S (Scandinavian Simvastatin Survival Study)
(52), WOSCOPS (West of Scotland Coronary Preven-
tion Study) (53), and LRC-CPPT (Lipid Research
Clinics Coronary Primary Prevention Trial) (54) trials
Figure 6
Coronary Heart Disease Risk of Homozygous Familial
Hypercholesterolemia Patients According to
Statin Treatment
Figure 5
Coronary Heart Disease Risk of
Heterozygous Familial Hypercholesterolemia
Patients According to Statin Treatment
Kaplan-Meier estimates of cumulative coronary heart disease-free survival among
patients with familial hypercholesterolemia according to statin treatment.
Reprinted with permission from Versmissen et al. (51).
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1940were likely enriched in FH patients (mean baseline
LDL-C of 189 mg/dl, 192 mg/dl, and 216 mg/dl,
respectively), and their results support the contention that
LDL-C lowering in patients with FH reduces CHD risk.Cox proportional hazards model with time-varying beneﬁt from statin therapy
comparing treated with untreated person-years for survival (A) and ﬁrst major
adverse cardiovascular event (MACE) (B) in patients with homozygous familial
hypercholesterolemia, with year of birth ﬁxed as the mean year of birth.
Reprinted with permission from Raal et al. (49).Current Therapies for FH
Risk assessment algorithms, such as the Framingham Risk
Score, do not apply to FH patients, who are considered a
special risk category. In the recently released American
Heart Association/American College of Cardiology guide-
lines, this category would include all those with an
LDL-C 190 mg/dl (5,55). It is estimated that FH is
diagnosed as such in only approximately 20% of patients
and that <10% of FH patients reach LDL treatment goals
(56). Concomitant with initiation of lipid-lowering medi-
cations, patients should be counseled on lifestyle changes,
including avoidance of smoking, regular exercise, and
adoption of a diet that is low in trans and saturated fats,
reﬁned sugars, and cholesterol; is rich in ﬁber and supple-
mented with plant sterols; and is calorie-appropriate for
body weight management. Diagnosis of FH warrants initi-
ation of drug therapy for LDL-C 190 mg/dl in all pa-
tients, including children older than 10 (44).
According to the National Lipid Association (57), the
goal of treatment for FH patients is a 50% reduction
in LDL-C, using moderate- to high-dose statin therapy
(Fig. 7). A consensus statement of the European Athero-
sclerosis Society on FH suggested LDL-C targets of <3.5
mmol/l (<135 mg/dl) for children, <2.5 mmol/l (<100
mg/dl) for adults, and <1.8 mmol/l (<70 mg/dl) for adults
with known CHD or diabetes (6). Higher risk patients,
such as those with prior CVD, comorbidities (diabetes,
hypertension), or additional risk factors (smoking, elevatedLp[a] levels) generally need multiple drugs to achieve an
LDL-C level <100 mg/dl. Statin monotherapy can de-
crease LDL-C up to 55% to 60%, but even that is normally
not enough to reach LDL-C goal in patients with clinically
manifested CHD (58). Ezetimibe, niacin, ﬁbrates, and
bile acid sequestrants are treatment options for intensiﬁca-
tion of therapy or for those intolerant of statins. Combi-
nation therapy can lead to an additional LDL-C reduction
of 20% to 30% (59–61). Most patients with CVD will
require 3 drugs to achieve an LDL-C level <100 mg/dl,
whereas an LDL of <70 mg/dl is beyond the reach of most
patients with FH.
Lipoprotein apheresis is used when drug therapy is inef-
fective or not tolerated and is normally performed biweekly
for HoFH and for severe HeFH when LDL is above 300
mg/dl (>200 for those with CAD) (62). Lipoprotein
apheresis uses either heparin (heparin-induced extracorpo-
real LDL precipitation or HELP) or dextran sulfate (Lip-
osorber, Kaneka Corporation, New York, New York) to
remove APOB-containing lipoproteins from plasma.
Apheresis results in 60% to 70% reduction in LDL-C and
Lp(a) immediately following the procedure, but levels usu-
ally return to baseline in 2 weeks, and the time-averaged
Figure 7 Treatment Algorithm for Patients With Familial Hypercholesterolemia
Adapted with permission from Goldberg et al. (24).
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1941daily LDL-C reduction is equivalent to w40%. Apheresis
also signiﬁcantly reduces levels of oxidized phospholipids
and lipoprotein-associated phospholipase A2 particles (63).
High Lp(a) levels are an approved indication for apheresis in
some European countries (64). In the United States,
approval is granted on a case-by-case basis. Randomized
trials are not feasible with apheresis, but observational
studies suggest a signiﬁcant reduction in events following
apheresis compared to the period before apheresis initiation
(65,66). A recent study conducted by 1 of the authors of this
review showed that lipoprotein apheresis also causes a sub-
stantial reduction in plasma PCSK9 levels (67).Recently Approved Therapies for HoFH
The microsomal triglyceride transfer protein (MTP) in-
hibitor lomitapide (Juxtapid, Aegerion Pharmaceuticals,
Inc., Cambridge, Massachusetts) and the APOB antisense
oligonucleotide mipomersen (Kynamro, Genzyme Corpo-
ration, Cambridge, Massachusetts) were recently approved
by the Food and Drug Administration (FDA) as orphan
drugs for LDL-C lowering as an adjunct to diet and other
lipid-lowering drugs in patients with HoFH. Lomitapide
was also approved by European Medicines Agency, whereasmipomersen was not. The FDA has not deﬁned explicit
criteria for the diagnosis of HoFH, and therefore, a clinical
diagnosis is needed for initiating therapy, and genetic
conﬁrmation is not required. The safety and effectiveness of
lomitapide and mipomersen have not been evaluated in
patients without HoFH, and these agents’ effects on CVD
morbidity and mortality is not known. Because of the risk
of hepatotoxicity, lomitapide and mipomersen are available
only through a Risk Evaluation and Mitigation Strategy
(REMS) program, and only certiﬁed healthcare providers
and pharmacies may prescribe and distribute them. The
consequences of lomitapide- and mipomersen-induced
aminotransferase elevation and hepatic fat are unknown
and should be carefully monitored in practice.
Microsomal triglyceride transfer protein inhibitor
lomitapide. Figure 8 describes the process of APOB
production and the role of MTP in creating very-low-
density lipoprotein (VLDL) particles. MTP is the key
protein that delivers the lipid droplet to APOB, crucial for
the assembly and secretion of APOB-containing lipopro-
teins in liver and intestine (68,69). Inhibition of MTP
decreases the secretion of chylomicrons and VLDL and
also causes reduced production of LDL (68). The pub-
lished clinical experience includes 35 HoFH patients, age
Figure 8 Lipoprotein Assembly and Secretion from Liver and Intestine
Effects of lomitapide and mipomersen. (Top) Intracellular assembly of triglyceride-rich lipoproteins from the transfer of the lipid droplet (LD) to apolipoprotein B-100 (APOB-100)
in the liver (left) and APOB-48 in the intestine (right) mediated by microsomal triglyceride transfer protein (MTP) and resulting in secretion of very-low-density lipoprotein (VLDL)
from hepatocytes and chylomicrons from enterocytes. (Bottom) Effects of the newly approved orphan drugs lomitapide and mipomersen. Lomitapide inhibits MTP activity in both
liver and intestine, whereas mipomersen stops production of hepatic APOB-100 and has no effect on intestinal lipoprotein production.
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1942>18 years, and mean age of 30.7  10.6 years in 2 studies
(70,71), and 84 patients with moderate hypercholesterole-
mia in another study (72). The main study was a single-
arm, open-label trial in which 29 patients with HoFH
were treated for 26 weeks with dose escalation from 5 to
60 mg/day and were followed until week 78 for safety
assessment. Twenty-three patients completed the full
study of a median dose of 40 mg/day, baseline LDL-C of
336 mg/dl, and pre-existing treatment including statinsFigure 9 Effect of Lomitapide on Low-Density Lipoprotein Cholestero
Mean percent changes in low-density lipoprotein cholesterol (LDL-C), TC, and apolipoprot
Reprinted with permission from Cuchel et al. (71).(93%), other lipid drugs (79%), and lipoprotein apheresis
(62%). Mean LDL-C was reduced by 50% (to 166 mg/dl)
at week 26, 44% (to 197 mg/dl) at week 52, and by 38% (to
208 mg/dl) at week 78 (Fig. 9). Lp(a) levels were reduced
by 15% at 26 weeks, but the effect disappeared by 78
weeks. Patients were instructed to eat a low-fat diet
(<20% energy) and to take daily fat-soluble vitamins. Five
patients (17%) discontinued treatment mainly due to
gastrointestinal symptoms of diarrhea and nausea. Fourl Levels
ein B (APOB) levels from baseline to week 26 following treatment with lomitapide.
Figure 10 Effect of Mipomersen on Low-Density Lipoprotein Cholesterol Levels
Mean percentage change from baseline (week 0) to primary efﬁcacy time point for low-density lipoprotein cholesterol (LDL-C) (A), apolipoprotein B (APOB) (B), and lipoprotein (a)
(Lp(a)) (C) in patients with homozygous familial hypercholesterolemia (HoFH) treated with subcutaneous mipomersen, 200 mg/week, or placebo. Error bars indicate 95%
conﬁdence interval (CI). Reprinted with permission from Raal et al. (74).
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1943patients (13.8%) had transaminase levels >5 normal, and
10 of 29 patients (34%) had at least 1 transaminase level
>3 above normal, all of which resolved after dose
reduction or discontinuation. Hepatic fat increased from
1% to 6%. No published data are available for the post-
launch clinical experience.
Antisense oligonucleotide against APOB-100 mipomersen.
Antisense oligonucleotides (ASO) are chemically modiﬁed
nucleic acids that bind to a target mRNA, leading to its
degradation, thereby reducing protein synthesis (Fig. 8).
ASOs are suitable for treating diseases that are caused by
or contribute to hepatic protein overproduction. APOB-100 is expressed in the liver and is essential for synthesis
and integrity of VLDL and LDL, thus representing an
ideal target for ASO therapy. The speciﬁc ASO mipo-
mersen binds to APOB-100 mRNA and creates a double-
stranded RNA complex that is cleaved by RNase H1,
preventing formation of APOB-100. Thus, mipomersen
inhibits VLDL synthesis and reduces plasma concentra-
tions of all APOB-containing lipoproteins, including
LDL. Mipomersen also effectively reduced median Lp(a)
by 21% to 39% across the 4 phase III mipomersen trials,
with the greatest reductions in HoFH (32%) and severe
hypercholesterolemia (39%) populations (73).
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1944Clinical studies have been performed with a total
of 775 subjects receiving 200 mg of mipomersen by weekly
subcutaneous injection for 26 weeks. To date, 4 phase 3
clinical trials have been performed in HoFH patients (74),
HeFH with CAD (75), severe HeFH (76) without CAD,
or with high CAD risk (77), as well as a 2-year open-label
extension trial in patients (n ¼ 141) (78). LDL-C re-
ductions ranged from 25% to 37%, with similar reductions
in APOB levels. The HoFH trial, the largest randomized
trial in HoFH to date, was a randomized, double blind,
placebo-controlled intention-to-treat trial of 51 patients with
either genetically deﬁned HoFH or untreated LDL-C levels
of >500 mg/dl plus xanthomas or evidence of HeFH in both
parents. Patients were taking statin, and most were also
taking other lipid-lowering drugs. In the placebo group,
baseline LDL-C was 402 mg/dl and declined to 390 mg/dl
at 26 weeks. In the mipomersen arm, baseline LDL-C was
440 mg/dl and was reduced to 324 mg/dl (Fig. 10). The
most common side effects were injection site reactions with
erythema, pain, tenderness, pruritus, and local swelling. Most
side effects were mild to moderate in severity and discon-
tinuation rate was 5% in the pooled phase 3 studies. Trans-
aminase elevations >3 upper limit of normal occurred in
8% to 12% of patients, and all returned to normal after
discontinuation of therapy. Hepatic steatosis was observed,
with a median increase in liver fat of 10% compared to
that of controls (76). In the open-label extension trial (78),
the mean changes in LDL-C from baseline to weeks 26
(n ¼ 130), 52 (n ¼ 111), 76 (n ¼ 66), and 104 (n ¼ 53)
were 28%, 27%, 27%, and 28%; and were 29%,
28%, 30%, and 31%, respectively, in APOB (78). Rates
of adverse events were similar to those reported in the
phase 3 trials, but median liver fat increase seen during
the initial 6 to 12 months appeared to diminish with
continued mipomersen exposure beyond 1 year and re-
turned toward baseline 24 weeks after last drug dose.
Some caveats of the trials include the facts that children
were included in the mipomersen but not the lomitapide trial
and that the lomitapide trial included patients previously
undergoing apheresis. The absolute reduction in LDL-C at
26 weeks was 170 mg/dl for lomitapide, although by 78
weeks there was some loss of efﬁcacy for lomitapide (absolute
reduction, 124 mg/dl) and 112 mg/dl for mipomersen.
Future Therapies: PCSK9 Inhibitors
PCSK9 is a protein produced by the liver and other tissues
and secreted into the circulation where it binds to and leads
to degradation of LDLR (7). Thus, PCSK9 acts as the
terminator of the long life cycle of LDLR, which spans
hundreds of recycling events. PCSK9 gain-of-function mu-
tations cause an FH phenotype, whereas loss-of-function
mutations cause low cholesterol and protection from CVD
(79). This has provided the rationale and impetus to develop
inhibitors of PCSK9 to lower LDL-C. Eleven clinical trials
have been published thus far with monoclonal antibodies
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1945administered by subcutaneous injection (Table 2) (80–90).
Phase 1 and 2 studies in a variety of subjects, including
patients with HeFH, have shown potent reductions in
LDL-C ranging from 30% to 75%. Similar reductions in
APOB are observed, but triglycerides are reduced only
modestly, and HDL-C levels are unchanged. Interestingly,
Lp(a) levels are also reduced 10% to 50%, but the mecha-
nisms through which this occurs have not been determined
(16). Finally, a recent study in 8 patients with both true
HoFH and compound HeFH demonstrated a 14% to 17%
reduction (absolute reduction, 70.6 mg/dl; range, 23
to 228 mg/dl) in LDL-C (89). Interestingly, the effect was
exclusive for the 6 patients with remaining LDLR function.
Even though the 2 HoFH receptor-negative patients had no
signiﬁcant LDL-C reduction, their Lp(a) levels were
reduced to the same extent (w12% to 20% depending on
dosage) as in LDLR-defective subjects, suggesting that
PCSK9 may be involved in Lp(a) metabolism regardless of
LDLR. Initial studies with PCSK9 inhibitors show a
favorable side effect proﬁle and no evidence of hepatic stea-
tosis, myalgia, or transaminase elevation. Phase 3 studies are
ongoing. A recent report showed that the alternative approach
of inhibiting PCSK9 expression via RNA interference was
also effective, causing reduction in plasma PCSK9 and LDL-
C levels by 70% and 50%, respectively (90).
There are 2 phase III outcome trials in progress, including
ODYSSEY (Evaluation of Cardiovascular Outcomes After
an Acute Coronary Syndrome During Treatment With
Alirocumab SAR236553 (REGN727); NCT01663402) and
FOURIER (Further Cardiovascular Outcomes Research
With PCSK9 Inhibition in Subjects With Elevated Risk;
NCT01764633). If approved, these drugs may revolutionize
our approach to patients with severe hypercholesterolemia,
including FH, with the potential to drastically reduce CVD
rates in these groups of high-risk patients.
Conclusions
ADH is a disease caused by mutations in genes (LDLR,
APOB, PCSK9) affecting the efﬁcacy of LDL removal
from the circulation. However, recent evidence suggests
that many patients with a clinical FH phenotype do not
carry mutations in these genes. Because it is expensive and
not covered by insurance, genetic testing to diagnose
ADH may lead to a paradoxical downgrading of status for
many patients whose genetic cause for the elevated LDL-
C is not determined. Patients with extreme hypercholes-
terolemia have an elevated risk of ischemic events
regardless of the genotype. Our focus should be on iden-
tiﬁcation and management of extreme hypercholesterole-
mia, with a phenotypic cascade approach to identify
affected family members when appropriate. New medica-
tions approved for management of HoFH have high-
lighted the necessity of a new and practical way to
categorize severe inherited LDL-C elevation. An approach
based on plasma LDL-C levels is justiﬁable, inexpensive,and sensitive by deﬁnition. Novel agents in development,
such as PCSK9 inhibitors, appear to be ideally suited to
ﬁnally provide a method for getting most FH patients to
LDL-C treatment goals.
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